# L_2016195EN.01001101.xml

| 20.7.2016 | EN | Official Journal of the European Union | L 195/11 |
| --- | --- | --- | --- |

20.7.2016

EN

Official Journal of the European Union

L 195/11

---

COMMISSION REGULATION (EU) 2016/1179

of 19 July 2016

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:

| (1) | Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC (2). |
| --- | --- |

(1)

Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC (2).

| (2) | Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted. However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017. |
| --- | --- |

(2)

Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted. However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017.

| (3) | Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances. |
| --- | --- |

(3)

Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.

| (4) | With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A. However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm). It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form. |
| --- | --- |

(4)

With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A. However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm). It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form.

| (5) | With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification. However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission. |
| --- | --- |

(5)

With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification. However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission.

| (6) | Regulation (EC) No 1272/2008 should be amended accordingly. |
| --- | --- |

(6)

Regulation (EC) No 1272/2008 should be amended accordingly.

| (7) | Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3), those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4) or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council (5). |
| --- | --- |

(7)

Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3), those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4) or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council (5).

| (8) | In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance. |
| --- | --- |

(8)

In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

| (9) | The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006, |
| --- | --- |

(9)

The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Article 1

Regulation (EC) No 1272/2008 is amended as follows:

| (1) | Annex VI is amended in accordance with the Annex to this Regulation; |
| --- | --- |

(1)

Annex VI is amended in accordance with the Annex to this Regulation;

| (2) | in Annex VI, Table 3.2 is deleted. |
| --- | --- |

(2)

in Annex VI, Table 3.2 is deleted.

Article 2

1.   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

2.   This Regulation shall apply from 1 March 2018.

Article 1(2) shall apply from 1 June 2017.

3.   By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 19 July 2016.

For the Commission

The President

Jean-Claude JUNCKER

---

(1)  
  OJ L 353, 31.12.2008, p. 1.

1

(2)  Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).

2

(3)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

3

(4)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

4

(5)  Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).

5

---

ANNEX

Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

| (a) | the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted; |
| --- | --- |

(a)

the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;

| (b) | the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:















  Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) |
| ‘006-035-00-8 | pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate | 245-430-1 | 23103-98-2 | Carc. 2
  Acute Tox. 3
  Acute Tox. 3
  Skin Sens. 1
  Aquatic Acute 1 Aquatic Chronic 1 | H351
  H331
  H301
  H317
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H351
  H331
  H301
  H317
  H410 | | M = 10
  M = 100’ | |
| ‘029-002-00-X | dicopper oxide;
  copper (I) oxide | 215-270-7 | 1317-39-1 | Acute Tox. 4
  Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H302
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H332
  H302
  H318
  H410 | | M = 100’ | |
| ‘602-020-00-0 | 1,2-dichloropropane;
  propylene dichloride | 201-152-2 | 78-87-5 | Flam. Liq. 2
  Carc. 1B
  Acute Tox. 4*
  Acute Tox. 4* | H225
  H350
  H332
  H302 | GHS02
  GHS08
  GHS07
  Dgr | H225
  H350
  H332
  H302’ | | | |
| ‘602-033-00-1 | chlorobenzene | 203-628-5 | 108-90-7 | Flam. Liq. 3
  Acute Tox. 4
  Skin Irrit. 2
  Aquatic Chronic 2 | H226
  H332
  H315
  H411 | GHS02
  GHS07
  GHS09
  Wng | H226
  H332
  H315
  H411’ | | | |
| ‘603-055-00-4 | propylene oxide;
  1,2-epoxypropane; methyloxirane | 200-879-2 | 75-56-9 | Flam. Liq. 1
  Carc. 1B
  Muta. 1B
  Acute Tox. 3
  Acute Tox. 3
  Acute Tox. 4
  STOT SE 3
  Eye Irrit. 2 | H224
  H350
  H340
  H331
  H311
  H302
  H335
  H319 | GHS02
  GHS08
  GHS06
  Dgr | H224
  H350
  H340
  H331
  H311
  H302
  H335
  H319’ | | | |
| ‘604-030-00-0 | bisphenol A;
  4,4′-isopropylidenediphenol | 201-245-8 | 80-05-7 | Repr. 1B
  STOT SE 3
  Eye Dam. 1
  Skin Sens. 1 | H360F
  H335
  H318
  H317 | GHS08
  GHS05 GHS07
  Dgr | H360F
  H335
  H318
  H317’ | | | |
| ‘604-092-00-9 | phenol, dodecyl-, branched; [1]
  phenol, 2-dodecyl-, branched; [2]
  phenol, 3-dodecyl-, branched; [3]
  phenol, 4-dodecyl-, branched; [4]
  phenol, (tetrapropenyl) derivatives [5] | 310-154-3 [1]
  [2]
  [3]
  [4]
  [5] | 121158-58-5 [1]
  [2]
  [3]
  210555-94-5 [4]
  74499-35-7 [5] | Repr. 1B
  Skin Corr. 1C
  Eye Dam. 1
  Aquatic Acute 1 Aquatic Chronic 1 | H360F
  H314
  H318
  H400
  H410 | GHS08
  GHS05
  GHS09
  Dgr | H360F
  H314
  H410 | | M = 10
  M = 10’ | |
| ‘605-013-00-0 | chloralose (INN);
  (R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral | 240-016-7 | 15879-93-3 | Acute Tox. 4*
  Acute Tox. 3
  STOT SE 3
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H301
  H336
  H400
  H410 | GHS06
  GHS09
  Dgr | H332
  H301
  H336
  H410 | | M = 10
  M = 10 | C’ |
| ‘605-022-00-X | glutaral; glutaraldehyde;
  1,5-pentanedial | 203-856-5 | 111-30-8 | Acute Tox. 2
  Acute Tox. 3
  STOT SE 3
  Skin Corr. 1B
  Resp. Sens. 1
  Skin Sens. 1A
  Aquatic Acute 1
  Aquatic Chronic 2 | H330
  H301
  H335
  H314
  H334
  H317
  H400
  H411 | GHS06
  GHS05
  GHS08
  GHS09
  Dgr | H330
  H301
  H335
  H314
  H334
  H317
  H410 | EUH071 | STOT SE 3; H335: 0,5 % ≤ C < 5 %
  M = 1’ | |
| ‘606-014-00-9 | chlorophacinone (ISO);
  2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione | 223-003-0 | 3691-35-8 | Repr. 1B
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 1
  STOT RE 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H330
  H310
  H300
  H372 (blood)
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H410 | | Repr. 1B; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,1 %
  STOT RE 2; H373 (blood):
  0,01 % ≤ C < 0,1 %
  M = 1
  M = 1’ | |
| ‘606-021-00-7 | N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone | 212-828-1 | 872-50-4 | Repr. 1B
  STOT SE 3
  Skin Irrit. 2
  Eye Irrit. 2 | H360D***
  H335
  H315
  H319 | GHS08
  GHS07
  Dgr | H360D***
  H335
  H315
  H319 | | STOT SE 3; H335: C ≥ 10 %’ | |
| ‘607-056-00-0 | warfarin (ISO);
  4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]
  (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]
  (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3] | 201-377-6
  [1]
  226-907-3
  [2]
  226-908-9
  [3] | 81-81-2 [1]
  5543-57-7
  [2]
  5543-58-8
  [3] | Repr. 1A
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 2
  STOT RE 1
  Aquatic Chronic 2 | H360D
  H330
  H310
  H300
  H372 (blood)
  H411 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H411 | | Repr. 1A; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,5 %
  STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’ | |
| ‘607-059-00-7 | coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin | 227-424-0 | 5836-29-3 | Repr. 1B
  Acute Tox. 2
  Acute Tox. 3
  Acute Tox. 2
  STOT RE 1
  Aquatic Chronic 1 | H360D
  H330
  H311
  H300
  H372 (blood)
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H311
  H300
  H372 (blood)
  H410 | | Repr. 1B; H360D: C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 1,0 %
  STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %
  M = 10’ | |
| ‘607-157-00-X | difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin | 259-978-4 | 56073-07-5 | Repr. 1B
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 1
  STOT RE 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H330
  H310
  H300
  H372 (blood)
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H410 | | Repr. 1B; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
  0,002 % ≤ C < 0,02 %
  M = 10
  M = 10’ | |
| ‘607-172-00-1 | brodifacoum (ISO);
  4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin | 259-980-5 | 56073-10-0 | Repr. 1A
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 1
  STOT RE 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H330
  H310
  H300
  H372 (blood)
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H410 | | Repr. 1A; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
  0,002 % ≤ C < 0,02 %
  M = 10
  M = 10’ | |
| ‘607-375-00-5 | flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin | 421-960-0 | 90035-08-8 | Repr. 1B
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 1
  STOT RE 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H330
  H310
  H300
  H372 (blood)
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H410 | | Repr. 1B; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,05 %
  STOT RE 2; H373 (blood):
  0,005 % ≤ C < 0,05 %
  M = 10
  M = 10’ | |
| ‘607-623-00-2 | diisobutyl phthalate | 201-553-2 | 84-69-5 | Repr. 1B | H360Df | GHS08
  Dgr | H360Df’ | | | |
| ‘613-166-00-X | flumioxazin (ISO);
  2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione | — | 103361-09-7 | Repr. 1B
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H400
  H410 | GHS08
  GHS09
  Dgr | H360D
  H410 | | M = 1 000
  M = 1 000 ’ | |
| ‘613-121-00-4 | chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide | 265-268-5 | 64902-72-3 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 1 000
  M = 100’ | |
| ‘616-011-00-4 | N,N-dimethylacetamide | 204-826-4 | 127-19-5 | Repr. 1B
  Acute Tox. 4*
  Acute Tox. 4* | H360D***
  H332
  H312 | GHS08
  GHS07
  Dgr | H360D***
  H332
  H312’ | | | |
| ‘616-037-00-6 | acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide | 251-899-3 | 34256-82-1 | Carc. 2
  Repr. 2
  Acute Tox. 4
  STOT SE 3
  STOT RE 2
  Skin Irrit. 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H361f
  H332
  H335
  H373 (kidney)
  H315
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H351
  H361f
  H332
  H335
  H373 (kidney)
  H315
  H317
  H410 | | M = 1 000
  M = 100’ | |
| ‘616-207-00-X | polyhexamethylene biguanide hydrochloride;
  PHMB | — | 32289-58-0
  27083-27-8 | Carc. 2
  Acute Tox. 2
  Acute Tox. 4
  STOT RE 1
  Eye Dam. 1
  Skin Sens. 1B
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H330
  H302
  H372 (respiratory tract) (inhalation)
  H318
  H317
  H400
  H410 | GHS08
  GHS06
  GHS05
  GHS09
  Dgr | H351
  H330
  H302
  H372 (respiratory tract) (inhalation)
  H318
  H317
  H410 | | M = 10
  M = 10’ | |

(b)

the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:

Index No

International Chemical Identification

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-factors

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘006-035-00-8

pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate

245-430-1

23103-98-2

Carc. 2

Acute Tox. 3

Acute Tox. 3

Skin Sens. 1

Aquatic Acute 1 Aquatic Chronic 1

H351

H331

H301

H317

H400

H410

GHS08

GHS06

GHS09

Dgr

H351

H331

H301

H317

H410

M = 10

M = 100’

‘029-002-00-X

dicopper oxide;

copper (I) oxide

215-270-7

1317-39-1

Acute Tox. 4

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H302

H318

H410

M = 100’

‘602-020-00-0

1,2-dichloropropane;

propylene dichloride

201-152-2

78-87-5

Flam. Liq. 2

Carc. 1B

Acute Tox. 4*

Acute Tox. 4*

H225

H350

H332

H302

GHS02

GHS08

GHS07

Dgr

H225

H350

H332

H302’

‘602-033-00-1

chlorobenzene

203-628-5

108-90-7

Flam. Liq. 3

Acute Tox. 4

Skin Irrit. 2

Aquatic Chronic 2

H226

H332

H315

H411

GHS02

GHS07

GHS09

Wng

H226

H332

H315

H411’

‘603-055-00-4

propylene oxide;

1,2-epoxypropane; methyloxirane

200-879-2

75-56-9

Flam. Liq. 1

Carc. 1B

Muta. 1B

Acute Tox. 3

Acute Tox. 3

Acute Tox. 4

STOT SE 3

Eye Irrit. 2

H224

H350

H340

H331

H311

H302

H335

H319

GHS02

GHS08

GHS06

Dgr

H224

H350

H340

H331

H311

H302

H335

H319’

‘604-030-00-0

bisphenol A;

4,4′-isopropylidenediphenol

201-245-8

80-05-7

Repr. 1B

STOT SE 3

Eye Dam. 1

Skin Sens. 1

H360F

H335

H318

H317

GHS08

GHS05 GHS07

Dgr

H360F

H335

H318

H317’

‘604-092-00-9

phenol, dodecyl-, branched; [1]

phenol, 2-dodecyl-, branched; [2]

phenol, 3-dodecyl-, branched; [3]

phenol, 4-dodecyl-, branched; [4]

phenol, (tetrapropenyl) derivatives [5]

310-154-3 [1]

[2]

[3]

[4]

[5]

121158-58-5 [1]

[2]

[3]

210555-94-5 [4]

74499-35-7 [5]

Repr. 1B

Skin Corr. 1C

Eye Dam. 1

Aquatic Acute 1 Aquatic Chronic 1

H360F

H314

H318

H400

H410

GHS08

GHS05

GHS09

Dgr

H360F

H314

H410

M = 10

M = 10’

‘605-013-00-0

chloralose (INN);

(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral

240-016-7

15879-93-3

Acute Tox. 4*

Acute Tox. 3

STOT SE 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H336

H400

H410

GHS06

GHS09

Dgr

H332

H301

H336

H410

M = 10

M = 10

C’

‘605-022-00-X

glutaral; glutaraldehyde;

1,5-pentanedial

203-856-5

111-30-8

Acute Tox. 2

Acute Tox. 3

STOT SE 3

Skin Corr. 1B

Resp. Sens. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 2

H330

H301

H335

H314

H334

H317

H400

H411

GHS06

GHS05

GHS08

GHS09

Dgr

H330

H301

H335

H314

H334

H317

H410

EUH071

STOT SE 3; H335: 0,5 % ≤ C < 5 %

M = 1’

‘606-014-00-9

chlorophacinone (ISO);

2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione

223-003-0

3691-35-8

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,1 %

STOT RE 2; H373 (blood):

0,01 % ≤ C < 0,1 %

M = 1

M = 1’

‘606-021-00-7

N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone

212-828-1

872-50-4

Repr. 1B

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

H360D***

H335

H315

H319

GHS08

GHS07

Dgr

H360D***

H335

H315

H319

STOT SE 3; H335: C ≥ 10 %’

‘607-056-00-0

warfarin (ISO);

4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]

(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]

(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]

201-377-6

[1]

226-907-3

[2]

226-908-9

[3]

81-81-2 [1]

5543-57-7

[2]

5543-58-8

[3]

Repr. 1A

Acute Tox. 1

Acute Tox. 1

Acute Tox. 2

STOT RE 1

Aquatic Chronic 2

H360D

H330

H310

H300

H372 (blood)

H411

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H411

Repr. 1A; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,5 %

STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’

‘607-059-00-7

coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin

227-424-0

5836-29-3

Repr. 1B

Acute Tox. 2

Acute Tox. 3

Acute Tox. 2

STOT RE 1

Aquatic Chronic 1

H360D

H330

H311

H300

H372 (blood)

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H311

H300

H372 (blood)

H410

Repr. 1B; H360D: C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 1,0 %

STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %

M = 10’

‘607-157-00-X

difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin

259-978-4

56073-07-5

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 10

M = 10’

‘607-172-00-1

brodifacoum (ISO);

4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin

259-980-5

56073-10-0

Repr. 1A

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1A; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 10

M = 10’

‘607-375-00-5

flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin

421-960-0

90035-08-8

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,05 %

STOT RE 2; H373 (blood):

0,005 % ≤ C < 0,05 %

M = 10

M = 10’

‘607-623-00-2

diisobutyl phthalate

201-553-2

84-69-5

Repr. 1B

H360Df

GHS08

Dgr

H360Df’

‘613-166-00-X

flumioxazin (ISO);

2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione

—

103361-09-7

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410

M = 1 000

M = 1 000 ’

‘613-121-00-4

chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide

265-268-5

64902-72-3

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1 000

M = 100’

‘616-011-00-4

N,N-dimethylacetamide

204-826-4

127-19-5

Repr. 1B

Acute Tox. 4*

Acute Tox. 4*

H360D***

H332

H312

GHS08

GHS07

Dgr

H360D***

H332

H312’

‘616-037-00-6

acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide

251-899-3

34256-82-1

Carc. 2

Repr. 2

Acute Tox. 4

STOT SE 3

STOT RE 2

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H332

H335

H373 (kidney)

H315

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361f

H332

H335

H373 (kidney)

H315

H317

H410

M = 1 000

M = 100’

‘616-207-00-X

polyhexamethylene biguanide hydrochloride;

PHMB

—

32289-58-0

27083-27-8

Carc. 2

Acute Tox. 2

Acute Tox. 4

STOT RE 1

Eye Dam. 1

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H351

H330

H302

H372 (respiratory tract) (inhalation)

H318

H317

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H351

H330

H302

H372 (respiratory tract) (inhalation)

H318

H317

H410

M = 10

M = 10’

| (c) | the following entries are inserted in accordance with the order of the index numbers:















  Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) |
| ‘005-020-00-3 | disodium octaborate anhydrous; [1]
  disodium octaborate tetrahydrate [2] | 234-541-0 [1]
  234-541-0 [2] | 12008-41-2 [1]
  12280-03-4 [2] | Repr. 1B | H360FD | GHS08
  Dgr | H360FD’ | | | |
| ‘014-046-00-4 | e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] | — | — | Carc. 1B | H350i | GHS08
  Dgr | H350i | | | A’ |
| ‘014-047-00-X | glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] | — | — | Carc. 2 | H351 (inhalation) | GHS08
  Wng | H351 (inhalation) | | | A’ |
| ‘029-015-00-0 | copper thiocyanate | 214-183-1 | 1111-67-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | EUH032 | M = 10’ | |
| ‘029-016-00-6 | copper(II) oxide | 215-269-1 | 1317-38-0 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 100’ | |
| ‘029-017-00-1 | dicopper chloride trihydroxide | 215-572-9 | 1332-65-6 | Acute Tox. 4
  Acute Tox. 3
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H301
  H400
  H410 | GHS06
  GHS09
  Dgr | H332
  H301
  H410 | | M = 10’ | |
| ‘029-018-00-7 | tetracopper hexahydroxide sulphate; [1]
  tetracopper hexahydroxide sulphate hydrate [2] | 215-582-3 [1]
  215-582-3 [2] | 1333-22-8 [1]
  12527-76-3 [2] | Acute Tox. 4
  Aquatic Acute 1 Aquatic Chronic 1 | H302
  H400
  H410 | GHS07
  GHS09
  Wng | H302
  H410 | | M = 10’ | |
| ‘029-019-01-X | copper flakes (coated with aliphatic acid) | — | — | Acute Tox. 3
  Acute Tox. 4
  Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H331
  H302
  H319
  H400
  H410 | GHS06
  GHS09
  Dgr | H331
  H302
  H319
  H410 | | M = 10’ | |
| ‘029-020-00-8 | copper(II) carbonate--copper(II) hydroxide (1:1) | 235-113-6 | 12069-69-1 | Acute Tox. 4
  Acute Tox. 4
  Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H302
  H319
  H400
  H410 | GHS07
  GHS09
  Wng | H332
  H302
  H319
  H410 | | M = 10’ | |
| ‘029-021-00-3 | copper dihydroxide;
  copper(II) hydroxide | 243-815-9 | 20427-59-2 | Acute Tox. 2
  Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H330
  H302
  H318
  H400
  H410 | GHS06
  GHS05
  GHS09
  Dgr | H330
  H302
  H318
  H410 | | M = 10’ | |
| ‘029-022-00-9 | bordeaux mixture;
  reaction products of copper sulphate with calcium dihydroxide | — | 8011-63-0 | Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H332
  H318
  H410 | | M = 10’ | |
| ‘029-023-00-4 | copper sulphate pentahydrate | 231-847-6 | 7758-99-8 | Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H302
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H302
  H318
  H410 | | M = 10’ | |
| ‘082-013-00-1 | lead powder;
  [particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A
  Lact. | H360FD
  H362 | GHS08
  Dgr | H360FD
  H362 | | Repr. 1A; H360D: C ≥ 0,03 %’ | |
| ‘082-014-00-7 | lead massive:
  [particle diameter ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A
  Lact. | H360FD
  H362 | GHS08
  Dgr | H360FD
  H362’ | | | |
| ‘605-040-00-8 | hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]
  4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]
  3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3] | - [1]
  250-863-4 [2]
  257-187-9 [3] | 130066-44-3 [1]
  31906-04-4 [2]
  51414-25-6 [3] | Skin Sens. 1A | H317 | GHS07
  Wng | H317’ | | | |
| ‘607-716-00-8 | bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one | 249-205-9 | 28772-56-7 | Repr. 1B
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 1
  STOT RE 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H330
  H310
  H300
  H372 (blood)
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H410 | | Repr. 1B; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):
  0,0005 % ≤ C < 0,005 %
  M = 1
  M = 1’ | |
| ‘607-717-00-3 | difethialone (ISO);
  3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one | — | 104653-34-1 | Repr. 1B
  Acute Tox. 1
  Acute Tox. 1
  Acute Tox. 1
  STOT RE 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H330
  H310
  H300
  H372 (blood)
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360D
  H330
  H310
  H300
  H372 (blood)
  H410 | EUH070 | Repr. 1B; H360D:
  C ≥ 0,003 %
  STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
  0,002 % ≤ C < 0,02 %
  M = 100
  M = 100’ | |
| ‘607-718-00-9 | perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts | 206-801-3 [1]
  [2]
  [3] | 375-95-1 [1]
  21049-39-8 [2]
  4149-60-4 [3] | Carc. 2
  Repr. 1B
  Lact.
  Acute Tox. 4
  Acute Tox. 4
  STOT RE 1
  Eye Dam. 1 | H351
  H360Df
  H362
  H332
  H302
  H372 (liver, thymus, spleen)
  H318 | GSH08
  GSH07
  GHS05
  Dgr | H351
  H360Df
  H362
  H332
  H302
  H372 (liver, thymus, spleen)
  H318’ | | | |
| ‘607-719-00-4 | dicyclohexyl phthalate | 201-545-9 | 84-61-7 | Repr. 1B
  Skin Sens. 1 | H360D
  H317 | GHS08
  GHS07
  Dgr | H360D
  H317’ | | | |
| ‘608-067-00-3 | 3,7-dimethylocta-2,6-dienenitrile | 225-918-0 | 5146-66-7 | Muta. 1B | H340 | GHS08
  Dgr | H340’ | | | |
| ‘612-288-00-0 | bupirimate (ISO);
  5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate | 255-391-2 | 41483-43-6 | Carc. 2
  Skin Sens. 1B
  Aquatic Chronic 1 | H351
  H317
  H410 | GHS08
  GHS07
  GHS09
  Wng | H351
  H317
  H410 | | M = 1’ | |
| ‘612-289-00-6 | triflumizole (ISO);
  (1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine | — | 68694-11-1 | Repr. 1B
  Acute Tox. 4
  STOT RE 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H360D
  H302
  H373 (liver)
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Dgr | H360D
  H302
  H373 (liver)
  H317
  H410 | | M = 1
  M = 1’ | |
| ‘616-218-00-X | benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide | — | 1072957-71-1 | Acute Tox. 3
  Acute Tox. 3
  Aquatic Acute 1
  Aquatic Chronic 1 | H331
  H301
  H400
  H410 | GHS06
  GHS09
  Dgr | H331
  H301
  H410 | | M = 100
  M = 100’ | |
| ‘616-219-00-5 | fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide | — | 658066-35-4 | Aquatic Chronic 2 | H411 | GHS09 | H411’ | | | |
| ‘616-220-00-0 | pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea | 266-096-3 | 66063-05-6 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 1
  M = 1’ | |
| ‘617-023-00-2 | tert-butyl hydroperoxide | 200-915-7 | 75-91-2 | Muta. 2 | H341 | GHS08
  Wng | H341’ | | | |

(c)

the following entries are inserted in accordance with the order of the index numbers:

Index No

International Chemical Identification

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-factors

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘005-020-00-3

disodium octaborate anhydrous; [1]

disodium octaborate tetrahydrate [2]

234-541-0 [1]

234-541-0 [2]

12008-41-2 [1]

12280-03-4 [2]

Repr. 1B

H360FD

GHS08

Dgr

H360FD’

‘014-046-00-4

e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]

—

—

Carc. 1B

H350i

GHS08

Dgr

H350i

A’

‘014-047-00-X

glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]

—

—

Carc. 2

H351 (inhalation)

GHS08

Wng

H351 (inhalation)

A’

‘029-015-00-0

copper thiocyanate

214-183-1

1111-67-7

Aquatic Acute 1 Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

EUH032

M = 10’

‘029-016-00-6

copper(II) oxide

215-269-1

1317-38-0

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 100’

‘029-017-00-1

dicopper chloride trihydroxide

215-572-9

1332-65-6

Acute Tox. 4

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H400

H410

GHS06

GHS09

Dgr

H332

H301

H410

M = 10’

‘029-018-00-7

tetracopper hexahydroxide sulphate; [1]

tetracopper hexahydroxide sulphate hydrate [2]

215-582-3 [1]

215-582-3 [2]

1333-22-8 [1]

12527-76-3 [2]

Acute Tox. 4

Aquatic Acute 1 Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

M = 10’

‘029-019-01-X

copper flakes (coated with aliphatic acid)

—

—

Acute Tox. 3

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H331

H302

H319

H400

H410

GHS06

GHS09

Dgr

H331

H302

H319

H410

M = 10’

‘029-020-00-8

copper(II) carbonate--copper(II) hydroxide (1:1)

235-113-6

12069-69-1

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H319

H400

H410

GHS07

GHS09

Wng

H332

H302

H319

H410

M = 10’

‘029-021-00-3

copper dihydroxide;

copper(II) hydroxide

243-815-9

20427-59-2

Acute Tox. 2

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H318

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H318

H410

M = 10’

‘029-022-00-9

bordeaux mixture;

reaction products of copper sulphate with calcium dihydroxide

—

8011-63-0

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H318

H410

M = 10’

‘029-023-00-4

copper sulphate pentahydrate

231-847-6

7758-99-8

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

M = 10’

‘082-013-00-1

lead powder;

[particle diameter < 1 mm]

231-100-4

7439-92-1

Repr. 1A

Lact.

H360FD

H362

GHS08

Dgr

H360FD

H362

Repr. 1A; H360D: C ≥ 0,03 %’

‘082-014-00-7

lead massive:

[particle diameter ≥ 1 mm]

231-100-4

7439-92-1

Repr. 1A

Lact.

H360FD

H362

GHS08

Dgr

H360FD

H362’

‘605-040-00-8

hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]

4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]

3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]

- [1]

250-863-4 [2]

257-187-9 [3]

130066-44-3 [1]

31906-04-4 [2]

51414-25-6 [3]

Skin Sens. 1A

H317

GHS07

Wng

H317’

‘607-716-00-8

bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one

249-205-9

28772-56-7

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):

0,0005 % ≤ C < 0,005 %

M = 1

M = 1’

‘607-717-00-3

difethialone (ISO);

3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one

—

104653-34-1

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

EUH070

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 100

M = 100’

‘607-718-00-9

perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts

206-801-3 [1]

[2]

[3]

375-95-1 [1]

21049-39-8 [2]

4149-60-4 [3]

Carc. 2

Repr. 1B

Lact.

Acute Tox. 4

Acute Tox. 4

STOT RE 1

Eye Dam. 1

H351

H360Df

H362

H332

H302

H372 (liver, thymus, spleen)

H318

GSH08

GSH07

GHS05

Dgr

H351

H360Df

H362

H332

H302

H372 (liver, thymus, spleen)

H318’

‘607-719-00-4

dicyclohexyl phthalate

201-545-9

84-61-7

Repr. 1B

Skin Sens. 1

H360D

H317

GHS08

GHS07

Dgr

H360D

H317’

‘608-067-00-3

3,7-dimethylocta-2,6-dienenitrile

225-918-0

5146-66-7

Muta. 1B

H340

GHS08

Dgr

H340’

‘612-288-00-0

bupirimate (ISO);

5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate

255-391-2

41483-43-6

Carc. 2

Skin Sens. 1B

Aquatic Chronic 1

H351

H317

H410

GHS08

GHS07

GHS09

Wng

H351

H317

H410

M = 1’

‘612-289-00-6

triflumizole (ISO);

(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine

—

68694-11-1

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H302

H373 (liver)

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H360D

H302

H373 (liver)

H317

H410

M = 1

M = 1’

‘616-218-00-X

benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide

—

1072957-71-1

Acute Tox. 3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H400

H410

GHS06

GHS09

Dgr

H331

H301

H410

M = 100

M = 100’

‘616-219-00-5

fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide

—

658066-35-4

Aquatic Chronic 2

H411

GHS09

H411’

‘616-220-00-0

pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea

266-096-3

66063-05-6

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1’

‘617-023-00-2

tert-butyl hydroperoxide

200-915-7

75-91-2

Muta. 2

H341

GHS08

Wng

H341’

---